American Society of Clinical Oncology Genitourinary Cancers Symposium 2025

• Include:  videos +  pdf, size:  GB
• Target Audience: oncologists, urologists, radiation oncologists
• Sample video: contact me for sample video
• Information:

The American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2025 is a premier event focused on the latest advancements in prostate, bladder, kidney, and other genitourinary cancers. It brings together oncologists, researchers, and healthcare professionals to discuss cutting-edge treatments, clinical trials, and emerging therapies.

Here are some key details:

Location: San Francisco, CA

Program Highlights:

Prostate Cancer: Advances in radioligand therapies and androgen receptor pathway inhibitors.

Bladder Cancer: Innovations in antibody drug conjugates and immunotherapy.

Kidney Cancer: Biomarkers and new treatment strategies.

Upper Tract Urothelial Carcinoma: Kidney-sparing approaches and perioperative therapies.

The American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2025 is tailored for professionals involved in genitourinary oncology, including:

Medical oncologists specializing in prostate, bladder, kidney, and other genitourinary cancers.

Urologists and radiation oncologists focused on multimodal treatment strategies.

Researchers and scientists presenting groundbreaking studies on biomarkers and emerging therapies.

Healthcare providers interested in the latest advancements in immunotherapy, targeted treatments, and surgical innovations.

Pharmaceutical and biotech professionals exploring novel drug developments.

Patient advocates and policy experts working to improve cancer care accessibility.

The symposium offers multidisciplinary perspectives, interactive sessions, and networking opportunities to enhance patient outcomes.

• Topics:

Thursday, February 13, 2025

7:00 AM-

8:00 AM

Complimentary Continental Breakfast

7:00 AM-

6:45 AM

Exhibits Open

8:00 AM-

9:40 AM

Oral Abstract Session A: Prostate CancerKosj Yamoah, MD, PhD—Chair

H. Lee Moffitt Cancer Center and Research InstituteChanning Judith Paller, MD—Chair

The Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPeter Hoskin, MD, FRCP, FRCR

Welcome of the Day

ABSTRACT 308: Gene signature predictor of dose-response to prostate radiation: Validation of PORTOS in phase III trials.

ABSTRACT 309: Radical prostatectomy (RP) versus radiotherapy (RT) in high-risk prostate cancer (HR-PCa): Emulated randomized comparison with individual patient data (IPD) from two phase III randomized trials (RCTs).

Edwin Posadas, MD, FACP

Cedars-Sinai Medical Center

Discussion

ABSTRACT 20: Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD).

Tanya B. Dorff, MD

City of Hope Comprehensive Cancer Center

Discussion

Panel Question and Answer

Break

Understanding Radioligand Therapies for Advanced Prostate CancerAngela Y Jia, MD, PhD—Chair

University Hospitals Seidman Cancer Center and Case Western Reserve UniversityDevaki Shilpa Surasi, MBBS—Chair

University of Texas at MD Anderson Cancer Center

PSMA-Based Therapy in Advanced Disease: Touching on Combination SequencingWilliam Kevin Kelly, DO

Thomas Jefferson University Hospital

Beyond PSMA-Targeted Agents for Advanced Disease

Danny Mena Cortes

Nuclear Medicine World

Seeing Is Believing: Radiographic Criteria to Assess Response

Panel Question and Answer

Poster Session A: Prostate Cancer

With Complimentary Boxed Lunch

Trials in Progress Poster Session A: Prostate Cancer

With Complimentary Boxed Lunch

Trainee and Early-Career Networking LuncheonView the networking faculty list here

Case-Based Session: Management of Biochemical Recurrence After Radiation Therapy for Localized Prostate CancerMichael Cookson, MD, MMHC, FACS—Chair

University of Oklahoma College of MedicineBarbara Jereczek-Fossa, MD—Chair

IEO European Institute of Oncology IRCCSMichael Cookson, MD, MMHC, FACS

University of Oklahoma College of Medicine

Recurrence After Radiation Therapy: Evaluation, Management, and Outcomes

Heather H. Cheng, MD, PhD

University of Washington

Medical Oncology

Juanita Crook, FRCPC

The University of British Columbia

Radiation Oncology

Thomas Polascik, MD

Duke University Division of Urologic Surgery

Urology (Ablative Focal)

Ashley Ross, MD, PhD

Northwestern University Feinberg School of Medicine

Urology (Salvage Surgery)

Alicia K. Morgans, MD, MPH, FASCO

Dana-Farber Cancer Institute

The Impact of Salvage Therapies: Functional Outcomes and Quality of Life

Panel Question and Answer

KeynotePeter Hoskin, MD, FRCP, FRCR – Chair

Mount Vernon Cancer Centre, University College London, and University of Manchester

Introduction of Dr. DahutWilliam L. Dahut, MD

American Cancer Society

Creative Innovation: Driving Science to Improve Patient-Centered CareQuestion and Answer

3:05 PM-

3:30 PM

Break

3:30 PM-

4:45 PM

Case-Based Session: Evolving Landscape of the Management of Oligometastatic DiseaseKaren E. Hoffman, MD, MHSc, MPH—Chair

The University of Texas MD Anderson Cancer CenterNicholas David James—Chair

Institute of Cancer Research, The Royal Marsden Hospital NHS Foundation TrustABSTRACT 15: World-wide oligometastatic prostate cancer (omPC) meta-analysis leveraging individual patient data (IPD) from randomized trials (WOLVERINE): An analysis from the X-MET collaboration.

Kenneth L. Gage, MD, PhD

H. Lee Moffitt Cancer Center and Research Institute

Radiology

Brandon A. Mahal, MD

University of Miami

Radiation Oncology

Kasmintan A. Schrader, PhD, MBBS

BC Cancer

Genetics

Sandy Srinivas, MD

Stanford School of Medicine

Medical Oncology

Panel Question and Answer

5:00 PM-

5:45 PM

Rapid Oral Abstract Session A: Prostate CancerMarjory Jolicoeur, MD, PhD, FRCPC—Chair

Panel Question and Answer

Poster Session A (Continued)

With Complimentary Wine and Cheese Reception

Trials in Progress Poster Session A (Continued)

With Complimentary Wine and Cheese Reception

Poster Walks: Prostate CancerMarjory Jolicoeur, MD, PhD, FRCPC

Hôpital Charles-LeMoyne

Poster Walk LeaderChanning Judith Paller, MD

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Poster Walk Leader

6:00 PM-

6:45 PM

Women’s Networking Reception

Friday, February 14, 2025

Complimentary Continental Breakfast

Exhibits Open

Oral Abstract Session B: Urothelial CarcinomaElizabeth A. Guancial, MD—Chair

Florida Cancer Specialists & Research InstituteNicholas I. Simon, MD, MSc—Chair

National Cancer InstituteAndrea B Apolo, MD

Welcome of the Day

Elizabeth R. Plimack, MD, FASCO, MS

Fox Chase Cancer Center, Temple Health

Discussion

Scot Anthony Niglio, MD, MS

National Institutes of Health Division of Occupational Health and Safety

Discussion

Panel Question and Answer

Break

Case-Based Session: Non-Muscle Invasive Bladder Cancer: Exploring Therapies Beyond Bacillus Calmette-GuérinBrian Christopher Baumann, MD—Chair

Springfield ClinicBogdana Schmidt, MD, MPH—Chair

University of Utah

The Changing World of Non-Muscle Invasive Bladder CancerCase Presentation

Girish S. Kulkarni, MD, PhD

Department of Surgical Oncology, Princess Margaret Cancer Center, University Health Network

Urology

Mark Tyson, MPH

Mayo Clinic Arizona

Urology

Tracy L Rose, MD

University of North Carolina at Chapel Hill

Medical Oncology

Panel Question and Answer

Poster Session B: Urothelial Carcinoma

With Complimentary Boxed Lunch

Trials in Progress Poster Session B: Urothelial Carcinoma

With Complimentary Boxed Lunch

Breakout Session: Emerging Trends and Advances in Germ Cell TumorsAditya Bagrodia, MD—Chair

University of California, San Diego HealthAnja Lorch, MD—Chair

Universitätsspital ZürichNabil Adra, MD

Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center

High-Dose Chemotherapy in Testicular Cancer: Current Evidence and Clinical Indications

Axel Heidenreich, MD

University Hospital of Cologne

Primary Retroperitoneal Lymph Node Dissection in Stage II Seminoma: Management Strategies and Current Controversies

Darren R. Feldman, MD

Memorial Sloan Kettering Cancer Center

Landscape of New Trials and Targets in Refractory Germ Cell Tumors

Panel Question and Answer

The ABCs of ADCs: Unleashing the Power of Antibody-Drug Conjugates in Advanced Bladder CancerKent William Mouw, MD, PhD—Chair

Dana-Farber Cancer Institute, Brigham and Women’s HospitalBenjamin Garmezy, MD—Chair

Sarah Cannon Research InstituteDi Maria Jiang, MD, MSc, FRCPC

Princess Margaret Hospital, University Health Network

Targeting Bladder Cancer With Antibody Drug Conjugates

Funda Meric-Bernstam, MD, FASCO

University of Texas MD Anderson Cancer Center

HER2 Antibody-Drug Conjugate Therapy: A New Frontier in Bladder Cancer

Daniel Castellano, MD

Servicio de Oncología Médica, Hospital Universitario 12 de Octubre

Overcoming Challenges of Antibody-Drug Conjugate Toxicity in Bladder Cancer

Terence W. Friedlander, MD

University of California, San Francisco Medical Center

Better Together? Exploring Novel Drug Combinations With Antibody-Drug Conjugates

Panel Question and Answer

Break

Panning for Gold: The Role of ctDNA as a Biomarker for Bladder CancerBernadett Szabados, MBBS—Chair

Barts Cancer CentreJoaquim Bellmunt, MD—Chair

Dana-Farber Cancer InstituteRoger Li, MD

H. Lee Moffitt Cancer Center and Research Institute

Capturing What You Cannot See: How Can ctDNA Be Used to Improve Clinical Staging for Upper Tract Disease?

Alexander William Wyatt, PhD

Vancouver Prostate Centre, University of British Columbia

Evolution of Ctdna Detection with Next Generation Technology

Nimira S. Alimohamed, FRCPC

Arthur Child Comprehensive Cancer Centre, University of Calgary

Potential Impact of ctDNA on Perioperative Management of Muscle-Invasive Bladder Cancer

Gillian Vandekerkhove, PhD, MSc

Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia

Beneath the Surface: Unleashing the Potential of Ctdna across the Spectrum of Urothelial Carcinoma

Panel Question and Answer

Rapid Oral Abstract Session B: Urothelial CarcinomaKatie S. Murray, DO, FACS, MS—Chair

ABSTRACT 666: Clinically advanced urothelial bladder cancer (CAUBC) in young onset bladder cancer (YOUC) patients: A genomic landscape study.

Panel Question and Answer

Poster Session B (Continued)

With Complimentary Wine and Cheese Reception

Trials in Progress Poster Session B (Continued)

With Complimentary Wine and Cheese Reception

Poster Walks: Urothelial CarcinomaElias Chandran, FRACP, MBBS

National Cancer Institute

Poster Walk LeaderArmine Smith, MD

Johns Hopkins University School of Medicine

Poster Walk Leader

Saturday, February 15, 2025

Complimentary Continental Breakfast

Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers

Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers

Oral Abstract Session C: Renal Cell CancerArpita Desai, MD—Chair

University of California, San FranciscoDaniel Shapiro—Chair

University of Wisconsin-MadisonTodd Matthew Morgan, MD

Welcome of the Day

Tian Zhang, MD, MHS

UT Southwestern University

Discussion

ABSTRACT 618: Prospective COTRIMS (Cologne trial of retroperitoneal lymphadectomy in metastatic seminoma) trial: Final results.

Clint Cary, MD, MBA, MPH

Indiana University Simon Comprehensive Cancer Center

Discussion

Panel Question and Answer

Break

Biomarkers and Adjuvant Therapy for Renal Cell Carcinoma: Current State and Future DirectionsShuchi Gulati, MD, MS, FACP—Chair

University of California, Davis Comprehensive Cancer CenterAxel Bex, MD, PhD—Chair

Simpa Samuel Salami, MD, MPH

University of Michigan

Biomarkers in Renal Cell Carcinoma: Dead End or Turning Point?

Samra Turajlic, MD, PhD

The Francis Crick Institute

The Future of Biomarkers in Renal Cell Carcinoma

Laurence Albiges, MD, PhD

Gustave Roussy, Université Paris Saclay

Adjuvant Therapy in Renal Cell Cancer: A Practical Guide

Panel Question and Answer

Poster Session C (Continued)

With Complimentary Boxed Lunch

Trials in Progress Poster Session C (Continued)

With Complimentary Boxed Lunch

Women in Genitourinary Cancers Networking LuncheonView the networking faculty list here

Poster Walks: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral CancersBrittney Cotta, MD

University of Texas MD Anderson Cancer Center

Poster Walk LeaderShuchi Gulati, MD, FACP, MS

UC Davis Comprehensive Cancer Center

Poster Walk Leader

12:45 PM-

​​​​​​​1:30 PM

Rapid Oral Abstract Session C: Renal Cell CancerBrittney Cotta, MD—Chair

ABSTRACT 444: Final overall survival and new ctDNA analysis in MET-driven advanced papillary renal cancer (CALYPSO).

ABSTRACT 1: EPIC-A: Phase II trial of cemiplimab plus standard of care chemotherapy followed by maintenance cemiplimab in locally advanced or metastatic penile carcinoma.

Panel Question and Answer

Case-Based Session: Failure of Immunotherapy in Renal Cell Cancer: What’s Next?Leslie K. Ballas, MD—Chair

Cedars-Sinai Medical CenterKathryn Hacker Gessner, MD, PhD—Chair

UNC School of MedicineMaria T. Bourlon, MD, MSc, FASCO

Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

Medical Oncology

Matthew T Campbell, MD, MS

The University of Texas MD Anderson Cancer Center

Medical Oncology

Raquibul Hannan, MD, PhD

University of Texas Southwestern Medical Center

Radiation Oncology

Viraj A. Master, MD, PhD

Emory School of Medicine

Urology

Panel Question and Answer